MétaCan
Menu
Back to cohort
Record W4400358441 · doi:10.1136/bmjopen-2023-078335

Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration

2024· review· en· W4400358441 on OpenAlexaff
Kristy Robledo, Shilo Lefresne, Yu Yang Soon, Arjun Sahgal, Mark B. Pinkham, Alan Nichol, Ross A. Soo, Ambika Parmar, Fiona Hegi‐Johnson, Mark Doherty, Benjamin Solomon, David Shultz, Ivan Weng Keong Tham, Adrian G. Sacher, Jeremy Tey, Cheng Nang Leong, Wee Yao Koh, Yiqing Huang, Yvonne Li En Ang, Jiali Low, Clement Yong, Mei Chin Lim, Ai Peng Tan, Chee Khoon Lee, Cheryl Ho

Bibliographic record

VenueBMJ Open · 2024
Typereview
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsPrincess Margaret Cancer CentreSunnybrook Health Science CentreHealth Sciences CentreUniversity of British ColumbiaBC Cancer Agency
FundersNational Medical Research CouncilMedical Research CouncilNational University Health SystemNational University Cancer Institute, SingaporeRoyal Australian and New Zealand College of RadiologistsCancer AustraliaAstraZeneca
KeywordsOsimertinibMedicineMeta-analysisProtocol (science)OncologyInternal medicineCancerEpidermal growth factor receptorPathologyErlotinib

Abstract

fetched live from OpenAlex

BACKGROUND: ) gene are a heterogeneous population who often develop brain metastases (BM). The optimal management of patients with asymptomatic brain metastases is unclear given the activity of newer-generation targeted therapies in the central nervous system. We present a protocol for an individual patient data (IPD) prospective meta-analysis to evaluate whether the addition of stereotactic radiosurgery (SRS) before osimertinib treatment will lead to better control of intracranial metastatic disease. This is a clinically relevant question that will inform practice. METHODS: mutant NSCLC and suitable to receive osimertinib both in the first-line and second-line settings (P); comparisons of SRS followed by osimertinib versus osimertinib alone (I, C) and intracranial disease control included as an endpoint (O). Systematic searches of Medline (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO), PsychInfo, ClinicalTrials.gov and the WHO's International Clinical Trials Registry Platform's Search Portal will be undertaken. An IPD meta-analysis will be performed using methodologies recommended by the Cochrane Collaboration. The primary outcome is intracranial progression-free survival, as determined by response assessment in neuro-oncology-BM criteria. Secondary outcomes include overall survival, time to whole brain radiotherapy, quality of life, and adverse events of special interest. Effect differences will be explored among prespecified subgroups. ETHICS AND DISSEMINATION: Approved by each trial's ethics committee. Results will be relevant to clinicians, researchers, policymakers and patients, and will be disseminated via publications, presentations and media releases. PROSPERO REGISTRATION: CRD42022330532.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.468
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0110.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0120.001
Bibliometrics0.0000.005
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0020.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.299
GPT teacher head0.521
Teacher spread0.222 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designMeta-analysis
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBMJ OpenSame topicBrain Metastases and TreatmentFrench-language works237,207